Novartis Back In AMD Game With ‘Potential Blockbuster’ Brolucizumab

 
• By Sten Stovall
  
Retina
Novartis' Brolucizumab Shows Further Advantages In nAMD Trials Versus Aflibercept • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Sensory

More from Therapeutic Category